British journal of clinical pharmacology

Semaglutide compared to liraglutide and their links to diabetes and heart disease in real-world data

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

GLP-1 receptor agonists semaglutide and liraglutide are approved for chronic weight management.

  • Both drugs are associated with a reduced risk of developing diabetes compared to placebo.
  • Semaglutide and liraglutide may lower the risk of cardiovascular disease compared to placebo.
  • The comparative effectiveness of semaglutide and liraglutide for diabetes and cardiovascular outcomes is not well understood.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Oct '25
Comparing Liraglutide, Semaglutide, and Dulaglutide in Veterans with Type 2 Diabetes
top 2% journal
cited by 5 papers
comparative study
May '26
Glucagon-like peptide-1 drugs and heart health in obese patients with artery disease but no diabetes
top 20% journal
journal article
Aug '25
Risk of Serious Diabetic Eye Disease with Common Diabetes Drugs Semaglutide, Dulaglutide, Liraglutide, and Exenatide in Everyday Care
top 5% journal
cited by 2 papers
multicenter study
Jun '26
Semaglutide and the risk of major heart and brain blood vessel problems in people with type 2 diabetes and rheumatoid arthritis
top 5% journal
Jun '26
Comparison of Different Diabetes Drugs Acting on GLP-1 Receptors and Their Effects on Kidney Health in Type 2 Diabetes
top 5% journal
journal article
Apr '26
Heart benefits of two diabetes drug types: GLP-1 receptor activators versus SGLT2 inhibitors
top 1% journal
journal article
Apr '25
Real-world use, benefits, and side effects of new weight-loss treatments based on GLP-1 receptor activators
top 5% journal
cited by 98 papers
journal article
Sep '25
How GLP-1 drugs compare in heart health for adults with type 2 diabetes and moderate heart risk
top 10% journal
cited by 5 papers
comparative study
Aug '25
Heart and kidney health linked to GLP-1 receptor drugs in adults with obesity
top 5% journal
cited by 4 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief